Biogen Inc. BIIB said Wednesday that it will halt the development and commercialization of its Alzheimer’s drug Aduhelm, which drew intense scrutiny of its U.S. regulatory approval process due to concerns about whether its benefits outweighed its risks.
The decision to discontinue Aduhelm “is not related to any safety or efficacy concerns,” Biogen said in a release, noting that it had been unable to find strategic partners or external financing for the program.
The…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here
